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ACA = anti-centromere antibodies; aCL = anticardiolipin antibodies; AFA = antifibrillarin/anti-U3-RNP; ANA = anti-nuclear antibodies; ANCA =
anti-neutrophil cytoplasmic antibodies; ANoA = anti-nucleolar antibodies; anti-RNAP = anti-RNA-polymerase antibodies; anti-Sm = anti-Smith anti-
bodies; aPL = antiphospholipid antibodies; β2gp I = β2 glycoprotein I antibodies; CENP = centromeric nucleoprotein; CIE = counterimmuno-
electrophoresis; CREST = a variant of SSc defined by the presence of calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly,
and telangectasia; CTD = connective tissue diseases; dcSSc = diffuse cutaneous systemic sclerosis; DLCO = diffusion capacity for carbon
monoxide; DM = dermatomyositis; ELISA = enzyme-linked immunosorbent assay; FVC = forced vital capacity; HLA = human leukocyte antigen; IB =
immunoblotting; ID = immunodiffusion; IIF = indirect immunofluorescence; IP = immunoprecipitation; lcSSc = limited cutaneous systemic sclerosis;
MCTD = mixed connective tissue disease; PFT = pulmonary function tests; PM = polymyositis; PM/SSc = myositis/scleroderma overlap; RLD =
restrictive lung disease; RNP = ribonucleoprotein; SLE = systemic lupus erythematosus; snRNP = small nuclear RNP; SSc = systemic sclerosis.
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Introduction
Systemic sclerosis (scleroderma or SSc) is a hetero-
geneous disorder characterized by autoantibody subsets,
which in turn have their own clinical associations. Much
controversy resides in whether these autoantibodies con-
tribute directly to the pathology seen in SSc or whether they
are merely epiphenomena of the underlying disease
process. Nevertheless, various autoantibodies found in
patients with SSc carry significant value in diagnosis and in
predicting clinical outcomes (Fig.1). The autoantibodies
classically associated with SSc include anti-centromere
antibodies (ACA) and anti-Scl-70 (otherwise known as anti-
topoisomerase I or anti-topo I). In addition to these is the
less commonly occurring anti-nucleolar antibody (ANoA)
system, which comprises a mutually exclusive heteroge-
neous group of autoantibodies that produce nucleolar stain-
ing by indirect immunofluorescence (IIF) on cells from a
variety of species [1]. The most widely recognized of these
include anti-PM-Scl [2], antifibrillarin/anti-U3-ribonucleo-
protein (AFA) [3], anti-Th/To [4], and the anti-RNA-poly-
merase family (anti-RNAP), including anti-RNAP I [5], II [6],
and III [7] (although anti-RNAP frequently do not produce
nucleolar staining on IIF). In addition to these disease-spe-
cific antibodies, anti-Ku, anti-Ro, antiphospholipid antibod-
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Abstract
Scleroderma (systemic sclerosis) is associated with several autoantibodies, each of which is useful in
the diagnosis of affected patients and in determining their prognosis. Anti-centromere antibodies
(ACA) and anti-Scl-70 antibodies are very useful in distinguishing patients with systemic sclerosis
(SSc) from healthy controls, from patients with other connective tissue disease, and from unaffected
family members. Whereas ACA often predict a limited skin involvement and the absence of pulmonary
involvement, the presence of anti-Scl-70 antibodies increases the risk for diffuse skin involvement and
scleroderma lung disease. Anti-fibrillarin autoantibodies (which share significant serologic overlap with
anti-U3-ribonucleoprotein antibodies) and anti-RNA-polymerase autoantibodies occur less frequently
and are also predictive of diffuse skin involvement and systemic disease. Anti-Th/To and PM-Scl, in
contrast, are associated with limited skin disease, but anti-Th/To might be a marker for the
development of pulmonary hypertension. Other autoantibodies against extractable nuclear antigens
have less specificity for SSc, including anti-Ro, which is a risk factor for sicca symptoms in patients
with SSc, and anti-U1-ribonucleoprotein, which in high titer is seen in patients with SSc/systemic
lupus erythematosus/polymyositis overlap syndromes. Limited reports of other autoantibodies (anti-Ku,
antiphospholipid) have not established them as being clinically useful in following patients with SSc.
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ies (aPL), anti-Smith (anti-Sm), anti-U1-ribonucleoprotein
(anti-U1-RNP), and other autoantibodies are also found in
SSc, each with a degree of clinical significance.
The present review details the various autoantibodies
associated with SSc, their frequency (including in different
ethnic groups), clinical correlates, pathophysiology, and
genetic associations.
Anti-nuclear antibodies (ANA)
Since the early 1960s it has been known that ANA are
common in the sera of patients with SSc [8,9], reported in
as many as 95% and as few as 75% of patients with SSc
with an overall diagnostic sensitivity of 85% and speci-
ficity of 54% when tested by IIF as published in a recent
meta-analysis [10]. The presence of anti-Scl-70 and
anti-U1-RNP antibodies in the sera yields a speckled
appearance, whereas anti-Th/To, anti-AFA, and anti-PM-
Scl give a nucleolar staining pattern. Anti-RNAP I antibod-
ies yield a nucleolar staining, whereas those against
RNAP II and III give a speckled appearance or no fluores-
cence [10]. The specificity and sensitivity of ANA vary
depending on the antigen substrate used for the assay.
The use of HEp2 cells yields a better sensitivity for the
detection of nuclear antigens present during cell division
(for example centromere antigen) than the use of tissue
sections of murine liver or kidney [10]. ANA can also be
measured by enzyme-linked immunosorbent assay
(ELISA), a much less cumbersome technique now
employed by many commercial laboratories. Although
ANA by ELISA is appealing because the assay is auto-
mated, it often produces false positive results [10]. In
addition, ANA by ELISA can yield false negative results,
especially in patients with ANoA, and should not be used
in the diagnosis of SSc without corroborative IIF [10].
ACA
ACA were initially described in 1980 [11] when HEp-2
cells were used as the substrate for the ANA. ACA had
not been seen previously with the use of IIF on tissue sub-
strates such as mouse liver, because the tissues in ques-
tion undergo cell division much less commonly. ACA have
been most typically determined by their characteristic
staining pattern on immunofluorescence, giving rise to a
speckled appearance on HEp-2 cells [11]. Subsequently
was shown that SSc patients with ACA produce autoanti-
bodies recognized by immunoblotting (IB), which react
against six different centromeric proteins [12–20].
However, these distinctions have not been shown to have
clinical relevance. So far, six centromeric nucleoproteins
are known to be bound by sera from patients with SSc,
designated CENP-A through CENP-F. Molecular analyses
have shown that CENP-A is a 17kDa centromere-specific
histone H3-like protein [13]. CENP-B is an 80kDa haploid
DNA-binding protein [14–16]. CENP-C is a 140kDa chro-
mosomal component required for kinetochore assembly
[16,17]. CENP-D is a centromere antigen of unknown
function, with a molecular mass of 50kDa [18]. CENP-E is
a 312kDa kinesin-like motor protein [19]. CENP-F is a
nuclear matrix protein that accumulates in the nuclear
matrix during S phase, assembling onto kinetochores at
late G2 during mitosis [19,20].
All sera containing ACA react with CENP-B [21]. A solid-
phase ELISA has been established by using a cloned
fusion protein of CENP-B as antigen [21–24].
The frequency of ACA in patients with SSc has been
reported to be 20–30% overall, but it varies depending on
the ethnicity of the SSc patient. When determined by IIF,
ACA are rather specific for the diagnosis of SSc. They are
rarely found in healthy patients [25–27]. They are likewise
seldom found to be positive in patients with other connec-
tive tissue diseases (CTD) [25,26,28,29] and are rarely
found in unaffected relatives [30,31] (Table 1). When
found in patients evaluated for Raynaud’s phenomenon,
ACA can predict the future development of SSc [32–36].
The presence of ACA has long been strongly associated
with CREST, a variant of SSc, defined by the presence of
calcinosis, Raynaud’s phenomenon, esophageal dysmotil-
ity, sclerodactyly, and telangectasia [11]. Finding ACA can
also distinguish CREST serologically from patients with
other variants of SSc [34–37], from patients with other
CTD [26–28,34], and from patients with primary Ray-
naud’s phenomenon [34,38] (Table 2).
Although IIF remains the ‘gold standard’ in determining the
presence of autoantibodies in SSc, many commercial lab-
oratories have adopted ELISA testing to detect the pres-
ence of such autoantibodies. More recently, an ELISA
using a cloned fusion protein of CENP-B as an antigen
against which ACA are directed has shown no added sen-
sitivity in the diagnosis of CREST compared with other
patients with SSc, patients with primary Raynaud’s phe-
nomenon and patients with other CTD [22,23]. One must
be very cautious of the specificity of this type of testing,
although recent refinements have improved its perfor-
mance [23,24].
Figure 1
Prognosis and systemic sclerosis-associated autoantibodies.
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The presence of ACA generally carries a better prognosis
than many other SSc-associated autoantibodies. In addi-
tion, ACA are associated with certain cutaneous and car-
diopulmonary manifestations.
ACA are most often seen in the presence of limited cuta-
neous involvement [39,40], and are also correlated with
the presence of calcinosis [41] and ischemic digital loss in
patients with SSc [42].
Pulmonary disease occurs in more than 70% of patients
with SSc, second only to the esophagus in frequency of
visceral involvement. The presence of ACA has been
associated with a lower frequency of radiographic intersti-
tial pulmonary fibrosis and a lesser severity thereof
[37,39,40,43].
Lung involvement in SSc is defined by numerous mea-
sures, most commonly either by the presence of radi-
ographic interstitial fibrosis, but also by abnormal forced
vital capacity (FVC) or diffusion capacity for carbon
monoxide (DLCO) on pulmonary function tests (PFT).
Although pulmonary involvement can also be defined by
high-resolution computed tomography of the chest
(HRCT) or by bronchoscopy with alveolar lavage, no
studies have looked at the presence of autoantibodies in
SSc-associated lung disease diagnosed by these means.
The lack of uniform criteria employed for the definition of
restrictive lung disease (RLD) makes it difficult to compare
studies of PFT. ACA have been found in association with
a lower frequency of RLD in some studies [37,44] but not
others [45,46]. It is noteworthy that ACA-positive patients
are more likely to have an abnormal DLCO but a normal
chest radiograph and FVC [47], underscoring that pul-
monary hypertension, in the absence of hypoxia from pul-
monary fibrosis, is a more common feature of
ACA-positive patients with SSc.
Studies on two recent large cohorts of 1321 patients have
found there is a lower mortality in ACA-positive patients
than in those with positive anti-Scl-70 autoantibodies or
AnoA [41,48]. Within 10 years of diagnosis, patients who
are positive for ACA and negative for anti-Scl-70 or nega-
tive for AnoA had a significantly better survival [41,48].
There seems to be no clinical utility in serially following
ACA levels once the SSc patient has been found to be
positive for ACA. ACA-positive patients remained positive
in nearly all determinations, whether tested by IIF or IB
[49–51], and no correlation with extent of disease involve-
ment in any organ system has been established with ACA
levels as determined by ELISA [51].
The frequency of ACA in patients with SSc varies depend-
ing on their ethnicity. It is highest in Caucasians, where
they are found in approximately a third of those, compared
with a significantly lower frequency in Hispanic, African
American and Thai patients with SSc [52,53] (Table 3).
HLA-DRB1*01, HLA-DRB1*04, and HLA-DQB1*05 are
associated with the presence of ACA [53,54] and it
seems likely that the generation of ACA is influenced by
the presence of both human leukocyte antigen (HLA)-
DRB1 and HLA-DQB1 alleles [55]. In Caucasian and
Japanese patients with SSc, the presence of at least one
HLA-DQB1 allele not coding for leucine at position 26 of
the first domain was found to be necessary but not suffi-
cient to generate ACA [31,55].
Anti-Scl-70 (anti-topoisomerase I) antibodies
In 1979, a basic, heat-labile, chromatin-associated, nonhi-
stone 70kDa protein against which autoantibodies from
patients with SSc are detected was described; it was iso-
lated from rat liver nuclei with a combination of biologic
and immunologic methods. This was initially designated
Scl-70 [56]. Subsequent analyses revealed this response
to be directed against topoisomerase I [57].
Anti-Scl-70 antibodies have classically been determined
by double immunodiffusion techniques against calf or
rabbit thymus extract, including Ouchterlony and counter-
immunoelectrophoresis (CIE) [49]. However, ascertain-
ment of anti-Scl-70 antibodies by immunodiffusion (ID)
Table 1
Overall sensitivity and specificity of anti-centromere
antibodies by indirect immunofluorescence in diagnosis of
SSc
SSc versus: Sensitivity (%) Specificity (%)
Normal controls 33*† 99.9*†
Other connective tissue diseases 31* 95†–97*
Primary Raynaud’s phenomenon 24* 90*
Non-SSc relatives 19* >99†*
*Reference [35]. †Reference [36].
Table 2
Overall sensitivity and specificity of anti-centromere
antibodies by indirect immunofluorescence in diagnosis of
CREST [40]
CREST versus: Sensitivity (%) Specificity (%)
Normal controls 65 99.9
Other connective tissue diseases 61 98
Primary Raynaud’s phenomenon 60 83
SSc 61 8483
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usually requires 2–3 days and is difficult to automate. To
circumvent this problem, IB and ELISA have been intro-
duced more recently [24,57,58]. Topoisomerase I, initially
purified from calf thymus glands, was used as antigen
[59], although more recent studies have used recombi-
nant topoisomerase I fusion proteins as the substrate for
the ELISAs [60].
Anti-Scl-70 antibodies are found in 15–20% of patients
with SSc by ID [35,36]. When determined by ID, anti-
Scl-70 autoantibodies are virtually never seen in healthy
controls [30,34–36,58] or in non-affected relatives of
patients with SSc [30,31], nor in those patients with other
CTD [28,29] or primary Raynaud’s phenomenon
[28,29,35,36] (Table 4). As with ACA, the presence of
anti-Scl-70 antibodies in a patient initially evaluated for
Raynaud’s phenomenon can confer an increase in the
future development of SSc [33]. The identification of anti-
Scl-70 antibodies by IB or ELISA carries a similar speci-
ficity to that of ID, with overall higher sensitivity in earlier
studies [34–36,52,58,59]. However, a recent article
raises concern about the specificity of anti-Scl-70 ELISA
assays for SSc, reporting positive results in sera of
patients with systemic lupus erythematosus (SLE) that
were correlated with disease activity, although this was
not reproducible by ID [61].
ACA and anti-Scl-70 antibodies are virtually always mutu-
ally exclusive, being present in less than 0.5% of all
patients with SSc simultaneously [35,36,41,48,62].
Anti-Scl-70 antibodies are found in about 40% of patients
with diffuse cutaneous systemic sclerosis (dcSSc) and
less than 10% of patients with limited cutaneous systemic
sclerosis (lcSSc) [35,36].
The frequency of anti-Scl-70 antibodies in SSc with pul-
monary fibrosis is about 45% [35]. Anti-Scl-70 antibodies
have been associated with both the presence and severity
of radiographic interstitial pulmonary fibrosis [39,47],
whether determined by ID, IB, immunoprecipitation (IP), or
ELISA [43]. Anti-Scl-70 antibodies have also been found
Table 3
Major histocompatibility complex class II associations with autoantibodies seen in patients with SSc
Autoantibodies HLA association Comments References
ACA HLA-DRB1
DRB1*01 In Hispanics and Caucasians [53–55]
DRB1*04
HLA-DQB1
DQB1*05 [53,55]
Anti-Scl-70 HLA-DRB1
DRB1*1101 In Caucasians and African Americans [53–55]
DRB1*1104 In Japanese [53,55]
DRB1*1502 In Hispanics and Caucasians [55,136]
HLA-DQB1
DQB1*0301 [71]
DQB1*0601
HLA-DPB1
DPB1*1301 In Caucasians [55]
DPB1*0901 In Japanese [136]
Anti-PM-Scl HLA-DQA1*0501 Not seen in Japanese [54,80]
HLA-DRB1*0301
Anti-Th/To HLA-DRB1*11 [87]
Anti-RNAP HLA-DQB1*0201 ? [91,93]
No association
Anti-U1-RNP HLA-DR2 In Japanese and Caucasians [117]
HLA-DR4
HLA-DQw5 In African Americans [118]
DQA1*0101
DQB1*0501
HLA-DQw8
DQB1*0302
Anti-U3-RNP/ HLA-DQB1*0604 ? [91,93]
antifibrillarin antibodies No association
Question marks denote associations seen in one study but not confirmed elsewhere. ACA, anti-centromere antibodies; HLA, human leukocyte
antigen; RNP, ribonucleoprotein.84
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in correlation with RLD [63] and with a higher rate of
decline in PFT [64], although this association is not univer-
sal [37,46].
Anti-Scl-70 antibodies carry an increased SSc-related
mortality rate, owing to the higher rate of right heart failure
in association with RLD and pulmonary fibrosis [65,66].
Although no convincing association has been established
for anti-Scl-70 and scleroderma renal crisis in other
studies, such an association has been shown in one study
of Japanese patients with SSc [67].
Repeated testing for anti-Scl-70 antibodies is unlikely to
be useful in clinical practice; although several recent
studies have examined serial determinations of anti-Scl-70
antibodies in patients with SSc, a clear role for this in
patient care has not been established. Patients who are
initially positive tend to remain so over time [45,68],
although in one recent study some patients with milder
disease became anti-Scl-70-negative later in their disease
course [69]. Three studies have shown variations in anti-
Scl-70 levels (determined by ELISA) with extent of
disease involvement and even seronegative conversion
with disease remission [68–70], although this was not
seen in others [51].
Unlike ACA, anti-Scl-70 antibody frequency has been
shown not to vary depending on ethnic distribution. The
presence of anti-Scl-70 antibodies is mediated by the
presence of the genes for both HLA-DRB1 and DQB1,
although primarily by the former in both Caucasian and
Japanese patients with SSc [55,71–72] (Table 3). HLA-
DRB1*11 is associated with anti-Scl-70 antibodies in all
ethnic groups, with HLA-DRB1*1101 and  HLA-
DRB1*1104 found in anti-Scl-70-positive Caucasians and
African Americans and HLA-DRB1*1104 found in anti-
Scl-70-positive Hispanics [53,55]. HLA-DPB1 alleles
have also been implicated in the anti-Scl-70 antibody
response in patients with SSc, specifically HLA-
DPB1*1301 in Caucasians and DPB1*0901 in Japanese
[55].
ANoA
Since at least 1970 it has been recognized that the ANoA
staining pattern of ANA was associated with SSc. ANoA
actually comprises a group of mutually exclusive and het-
erogeneous autoantibodies that exhibit a typical nucleolar
staining pattern of ANA by IIF on various cells (most often
HEp2 cells) [1]. They include anti-PM-Scl, anti-Th/To, anti-
U3-RNP, AFA, and anti-RNAP I, anti-RNAP II, and anti-
RNAP III. Anti-RNAP II and anti-RNAP III do not always
yield a nucleolar staining pattern by IIF.
ANoA have been reported in 15–40% of patients with
SSc [39,73]. Unlike with ACA and anti-Scl-70, the
number of published studies on frequency of ANoA is rela-
tively small. Nevertheless, specific ANoA are rarely seen in
healthy controls [1,74] nor in healthy non-affected rela-
tives of patients with SSc [75]. ANoA are perhaps less
specific for SSc than was previously thought, because
they can be found in patients with other diseases such as
SLE and Sjögren syndrome [76,77].
Anti-PM-Scl antibodies were the first of the AnoA to be
characterized in 1977. Originally discovered in patients
with myositis/scleroderma overlap syndrome (PM/SSc)
with the use of Ouchterlony ID techniques [78], anti-PM-
Scl are usually identified by IP techniques today [77].
Recently, the anti-PM-Scl autoantibodies have been
shown to target six human exosome components that
make up an RNA-processing complex, namely hRrp4p,
hRrp40p, hRrp41p, hRrp42p, hRrp46p and hCs14p.
hRrp4p and hRrp42p are most frequently targeted by the
anti-PM-Scl antibody [79]. The frequency of anti-PM-Scl
varies between different ethnic groups, ranging from about
3% of patients with SSc and 8% of patients with myositis
in Caucasians [1,78], to being absent from a large series
of 275 Japanese patients with SSc [43].
Anti-PM-Scl antibodies have been associated with the
PM/SSc overlap syndrome [80,81]. As many as 80% of
patients with anti-PM-Scl antibodies will have a PM/SSc
overlap syndrome [81]. Anti-PM-Scl antibodies are found
in as many as 50% of patients with PM/SSc overlap in
comparison with less than 2% of patients with SSc in
general [2,5]. The PM/SSc-associated overlap syndrome
is associated with a more benign and chronic course of
disease and responds to a low to moderate dose of corti-
costeroids [80]. Anti-PM-Scl antibodies predict limited
Table 4
Sensitivity and specificity of Anti-Scl-70 in diagnosis of SSc
SSc versus: Assay used Sensitivity (%) Specificity (%)
Normal controls ID 20* 100*
IB 41* 99.4*
ELISA 43* 100*
Overall 34† 99.6†
Other connective ID 26* 99.5*
tissue diseases
IB 40* 99*
ELISA 43* 90*
Overall 97.9†
Primary Raynaud’s ID 28* 98*
phenomenon
Non-SSc relatives ID 25.5* 100*†
*Reference [35]. †Reference [36]. ELISA, enzyme-linked
immunosorbent assay; IB, immunoblotting; ID, immunodiffusion.85
cutaneous involvement when they are present [43,75,82],
although less reliably than ACA. This is likely to be sec-
ondary to the relative infrequency of anti-PM-Scl antibod-
ies compared with ACA, reported in less than 15%
patients with lcSSc [43,75,82]. Anti-PM-Scl antibodies
are strongly linked to HLA-DQA1*0501 and  HLA-
DRB1*0301 [54] (Table 3).
After the discovery of anti-PM-Scl antibodies, the refine-
ment of IP assays using [32P]orthophosphate or
[35S]methionine-labeled cell extracts allowed the recogni-
tion of another ANoA, anti-Th/To, in 1983 [4,83]. The
Th/To antigen has recently been identified. Anti-Th/To
antibodies are directed against components of the ribonu-
clease MRP and ribonuclease P complexes, more fre-
quently Rpp25 and hPop1. The Th40 autoantigen is
identical to Rpp38 protein [84]. Anti-Th/To are present in
about 2–5% of patients with SSc, being perhaps more
common in the Japanese, and were previously virtually
never seen in healthy control patients (less than 1%) [47].
This no longer seems to be so, because anti-Th/To anti-
bodies have also been described in patients with SLE, PM
and primary Raynaud’s phenomenon [76,77]. Anti-Th/To
antibodies are also almost never seen in the presence of
ACA [76]. Like ACA, their presence most specifically pre-
dicts limited skin involvement [47,75,76,84], although
routine testing is hardly useful as anti-Th/To autoantibod-
ies are found so infrequently (Fig. 2).
Because of the low frequency of anti-Th/To antibodies, few
studies have addressed their clinical significance. One
report found that no particular clinical features were associ-
ated with anti-Th/To [47]. In another, anti-Th/To-positive
patients with lcSSc carried a worse prognosis [85] with a
smaller frequency of joint involvement but a greater fre-
quency of puffy fingers, small bowel involvement, hypothy-
roidism, and a greater risk for reduced survival at 10 years
[85], succumbing primarily to pulmonary arterial hyperten-
sion. In still another study, anti-Th/To antibodies were
described in those patients with SSc who developed the
combination of scleroderma renal crisis and pulmonary
hypertension without interstitial lung disease [86]. In a
study of sera from 172 patients with various CTD [77],
anti-Th/To antibodies were increased in those patients with
xerophthalmia, esophageal dysmotility and decreased
DLCO. The presence of anti-Th/To antibodies has been
associated with HLA-DRB1*11 [55,87] (Table 3).
Anti-RNAP I, anti-RNAP II, and anti-RNAP III were not dis-
covered until 1987 and 1993 [7,88]. Determined by IP
techniques, these specific autoantibodies are found in
about 20% of patients with SSc [5,82,89] and, like other
disease-specific autoantibodies, carry diagnostic and
prognostic value. The specificity of anti-RNAP I and anti-
RNAP III for SSc is similar and higher than that of anti-
RNAP II, which can also be found in patients with
SLE/SSc and overlap syndrome [90]. Anti-RNAP I and
anti-RNAP III almost invariably coexist [5,82,89].
Anti-RNAP antibodies are associated with diffuse cuta-
neous involvement and have the highest likelihood of
being associated with dcSSc than any other disease-spe-
cific autoantibodies apart from anti-Scl-70 [7,43,82,88,91,
92]. They are found in about 40% of patients with dcSSc.
The presence of anti-RNAP II antibodies has been found
to independently predict lower lung function, even when
ethnicity, age, smoking history, and disease duration were
considered simultaneously [64], although this is not uni-
formly seen [7].
Anti-RNAP antibodies, like anti-Scl-70 antibodies, are cor-
related with a higher rate of SSc-related mortality, though
not independently so. There exists a highly significant
association between anti-RNAP antibodies and right heart
failure unrelated to pulmonary fibrosis (probably related to
pulmonary hypertension), which accounts for this increase
[66].
Anti-RNAP I, anti-RNAP II, and anti-RNAP III were found to
be associated with HLA-DQB1*0201 in one study, and
no HLA association was seen in another [91,93] (Table 3).
In 1985, anti-U3-RNP antibodies were isolated by IP tech-
niques [94]. More recently it was shown that the mam-
malian U3 small nuclear RNP (snRNP) is one member of a
family of nucleolar snRNPs that are immunoprecipitable by
anti-fibrillarin autoantibodies [95]. AFA are present in
about 4% of patients with SSc and are mutually exclusive
with ACA, anti-Scl-70, and anti-RNAP [96]. AFA have also
been described in patients with SLE, UCTD, and primary
Raynaud’s phenomenon [77]. The frequency of AFA is
much higher in patients of African descent with SSc and
is reported to be as high as 16–22% compared with only
4% in Caucasian patients with SSc [40,88,95]. AFA are
highly specific for dcSSc [1,40,43,47,92,96] and when
found in African American patients with SSc are virtually
always associated with dcSSc [40,89,96]. Their presence
in Caucasian patients with SSc is associated with diffuse
skin involvement, but the correlation is not nearly as strong
[96]. AFA-positivity in those patients with dcSSc also has
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Figure 2
Skin involvement and autoantibody subset of systemic sclerosis.
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been associated with myositis, pulmonary hypertension,
and renal disease. These autoantibodies also identify a
younger subset of SSc patients with frequent internal
organ involvement. However, in patients with lcSSc the
presence of AFA did not predict pulmonary hypertension.
Strangely, for its degree of internal organ involvement,
AFA were not associated with a higher mortality rate,
although those who died tended to succumb to pulmonary
hypertension [96].
Although not seen in all studies [93], the autoantibody
response to U3-RNP was associated in one study with
HLA-DQB1*0604 [40] (Table 3).
Other autoantibodies
Although the autoantibodies discussed in this section are
much less specific to SSc than those already described,
the following do carry valuable information.
Anti-Ku antibodies
Anti-Ku autoantibodies were originally thought to be rela-
tively specific for SSc, although they have been reported
more recently in sera from patients with SLE, SSc, and
overlap syndrome [97,98]. By ELISA, IB, ID, or IP, a total
of 159 anti-Ku-positive patients were identified: one-third
had an overlap syndrome, 28% SLE, 4% dermatomyositis/-
polymyositis (DM/PM), 14% SSc, and 20% other autoim-
mune diseases. Of those patients with overlap syndrome,
nearly 65% had clinical features of scleroderma [98].
aPL
aPL, a group of autoantibodies composed of anticardi-
olipin antibodies (aCL), lupus anticoagulant antibody, and
β2 glycoprotein I antibodies (β2gpI), are found in the
antiphospholipid antibody syndrome but also in connec-
tion with various autoimmune, inflammatory, infectious, and
neoplastic conditions. aPL are correlated with arterial and
venous thromboses, livedo reticularis, recurrent fetal loss,
thrombocytopenia, and cerebral and myocardial infarction.
Although secondary antiphospholipid syndrome is rare in
SSc (found in less than 1% of scleroderma patients
[99,100]), the frequency of aPL in SSc is about 20–25%
(ranging widely from 0% to 63%) [100–107]. Of note,
though not widely recognized, aCL and ACA seem to be
mutually exclusive [105,106].
There is a great deal of interlaboratory variability in testing
aPL as measured by ELISA, which makes it difficult to
compare and interpret the association of this antibody
with various disease manifestations [104]. In addition, the
role of aPL in pathogenesis and determining long-term
outcomes in SSc is not clear at present.
The presence of aCL seems to be correlated with higher
extent of disease involvement in SSc as defined by the
presence of more skin and visceral involvement [100,105]
in some studies, although not in others [101,106]. In two
studies, aCL were also associated with myocardial
ischemia or necrosis [100], although not with the pres-
ence of valvular lesions or diastolic dysfunction.
In one study, coexisting β2gpI and aCL antibodies were
found to be significantly associated with the presence of
isolated pulmonary hypertension, and higher levels of
these antibodies were correlated with higher mean pul-
monary arterial pressure [104].
Although previously believed to have a potential role in the
vasculitic phenomenon observed in SSc [100,105], the
presence of aCL is not correlated with the presence of
vascular lesions, ischemic cutaneous lesions, or digital
ulcers [106,108]. aCL-positivity is less commonly present
in SSc patients with proximal skin involvement, scarring ,or
esophageal hypomotility and is more often associated with
limited cutaneous involvement [106]. Thus the clinical
utility of determining aCL in patients with SSc has not yet
been established.
Antibodies against extractable nuclear antigens
Anti-Sm and anti-U1-RNP antibodies
Autoantibodies against saline-soluble extractable nuclear
antigens, including those against Sm antigen and RNP,
are found in many CTD. The presence of anti-Sm antibod-
ies is considered to be highly specific for SLE [108] but
occasionally occurs in patients with SSc [108]. In con-
trast, anti-U1-RNP antibodies bind to RNP, a ribonucle-
ase-sensitive antigen involved in splicing heterogeneous
nuclear RNA into mRNA. These antibodies are associated
with a variety of CTD, including SLE, SSc, PM, and
overlap syndrome previously designated ‘mixed connec-
tive tissue disease’ (MCTD) [108].
Anti-Sm and anti-U1-RNP antibodies can be identified
by IP in agarose gel by using radial ID or CIE, ELISA, or
hemagglutination [24,108]. Of these techniques, CIE is
the most rapid; passive ID lacks sensitivity and is most
time consuming; hemagglutination is complicated when
both Sm and RNP are present; and although ELISA is the
most sensitive it does not have the same specificity as ID
techniques, particularly when anti-RNP antibodies are
present in low levels [24].
Anti-Sm antibodies are rarely found in patients with SSc
[108,109]. When found, they are most often present in
SSc patients with SLE overlap and portend a poor prog-
nosis with multiple serious organ involvement such as
lupus nephritis, renal crisis, and pulmonary hypertension
[109]. There is no evidence that the levels of anti-Sm anti-
bodies coincide with SSc severity [110].
The frequency of anti-U1-RNP antibodies in SSc is about
8% (ranging from 2% to 14%) [47,53,104,108]. Anti-
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U1-RNP antibodies in high titers are most often found in
association with an overlap syndrome/MCTD with a fre-
quency of more than 90% [108,111–114]. More recently,
the diagnosis of MCTD as a distinct entity has been dis-
puted [115], being thought of instead as a disease contin-
uum overlap between SLE, SSc, and DM/PM. Clinically,
the presence of anti-U1-RNP, whether seen in MCTD,
SLE, DM/PM, or SSc, usually portends a favorable
response to corticosteroids [108,111] and a more benign
prognosis with less tendency for systemic disease charac-
terized by less cutaneous [47,108,112], renal [108,112],
and central nervous system disease [43]. Anti-U1-RNP
antibodies in patients with CTD are associated with the
presence of Raynaud’s phenomenon [108,111], puffy
hands [47,104,111], sicca [111], pulmonary disease
[108,110,111,], arthritis/arthralgia [47,114], myositis
[47,108,111], and esophageal disease [108], although
this is not seen in all studies [116]. Septal hypertrophy
and cor pulmonale secondary to pulmonary hypertension
has also been linked to the presence of anti-U1-RNP anti-
bodies [43].
More recently, anti-U1-RNP antibodies have been
described to bind a snRNP known as p70 protein
(70kDa). These antibodies against p70, found in SSc and
MCTD by IB, are not detected in SLE. Their presence cor-
relates with pulmonary fibrosis, a decrease in FVC, and
joint involvement [110].
HLA class II associations with anti-U1-RNP antibodies are
less consistent. In some studies they have been associ-
ated with HLA-DR2 and DR4 [117]. In others, an
increased frequency of HLA-DQw5-associated
DQA1*0101 and DQB1*0501, and the HLA-DQw8-asso-
ciated allele DQB1*0302, was seen [118] (Table 3).
Anti-Ro antibodies
Anti-Ro antibodies do occur in patients with SSc, but at a
lower frequency than in those with SLE or Sjögren syn-
drome (less than 35%) [119]. However, Sjögren syn-
drome has been described in up to 20% of all patients
with SSc [120,121] with about one-third to one-half of
those with anti-Ro antibodies. Sjögren syndrome is actu-
ally associated with about 35% of SSc patients positive
for anti-Ro.
Less extensively studied autoantibodies in SSc
The association between more recently characterized
autoantibodies and the clinical manifestations of SSc has
been less well examined. One report described autoanti-
bodies recognizing granzyme B-cleaved autoantigens as
being specifically associated with ischemic digital loss in
lcSSc [122].
Anti-neutrophil cytoplasmic antibodies (ANCA) have been
reported at a low incidence in SSc (about 3%) without
any significantly associated clinical features [123],
although there are anecdotal reports of elevated anti-
myeloperoxidase antibodies associated with microscopic
polyangiitis in SSc [86]. A recent study identified two
patients with a positive ANCA and diffuse SSc. One
patient was weakly positive for anti-myeloperoxidase anti-
bodies in the absence of renal involvement and the other
was strongly positive for anti-proteinase 3 antibodies and
had rapidly progressive skin and lung involvement [124].
Whether or not this autoantibody system has any rele-
vance to SSc needs further study.
Autoantibodies against endothelial cell antigen have been
described in patients with SSc, supporting the hypothesis
that endothelial cell dysfunction and vascular injury are
required in the development of scleroderma. Anti-endothe-
lial cell antibodies were found to be correlated with pul-
monary fibrosis in patients with SSc in one study [125]
but not in another [126]. Anti-endothelial cell antibodies
have also been found in association with alveolo-capillary
involvement, pulmonary arterial hypertension, digital ulcers
and ischemia, severe Raynaud’s phenomenon and capil-
laroscopic abnormalities [126–128]. In addition, these
autoantibodies might provide useful information on prog-
nosis because there seems to be a trend toward more
severe disease and the presence of anti-endothelial anti-
bodies [128]. This autoantibody system clearly needs
further study.
A small number of patients with SSc develop autoantibod-
ies against the centrioles and mitotic apparatus, such as
the centrosomes [129,130]. Anti-centriole antibodies are
seen in association with primary Raynaud’s phenomenon
and scleroderma [131,132]. Anti-p80-coilin antibodies
have been isolated from the sera of five patients from a
serum bank of 810 Japanese patients with ‘collagen dis-
eases’. Of these, four had localized scleroderma and one
had primary Raynaud’s phenomenon [133]. The signifi-
cance of this autoantibody remains to be determined,
although its low prevalence makes it unlikely to be impor-
tant in the pathogenesis of SSc.
Antibodies against fibrillin-1 protein, an extracellular matrix
microfibrillar protein, have been found to be highly associ-
ated with SSc in most ethnic groups. In addition, patients
with diffuse SSc and CREST also had significantly higher
frequencies of anti-fibrillin-1 antibodies than did their con-
trols or other CTD patients [134].
Anti-histone antibodies can be seen in a variety of condi-
tions, including SSc. In one study, limited SSc was associ-
ated with the presence of IgM antibodies against histone
H1, whereas diffuse SSc was related to the presence of
IgG antibodies against the inner core molecules such as
H2B [135]. Given the low diagnostic value that anti-
histone antibodies have in other CTD (with the highest
Available online http://arthritis-research.com/content/5/2/8088
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prevalence in drug-induced SLE), this finding needs to be
confirmed further.
Summary
Significant serologic heterogeneity is well known to occur
in SSc. Although it remains controversial whether autoan-
tibodies seen in patients with SSc have an actual role in
pathogenesis, these serologic markers are useful in the
diagnosis and clinical management of scleroderma
patients (Table 5). ACA are most often found in Cau-
casians and in association with limited cutaneous involve-
ment, CREST, and isolated pulmonary hypertension. In
contrast, they are infrequently found in patients with pul-
monary fibrosis. ACA seem to be a marker for a better
prognosis, whereas anti-Scl-70 antibodies, found in
patients with dcSSc and pulmonary fibrosis, portend a
poor prognosis with increased SSc-related mortality. The
following of ACA and anti-Scl-70 levels over time has not
been shown to have clinical utility. Of the ANoA, anti-
PM-Scl and anti-Th/To antibodies are associated chiefly
with lcSSc (with anti-PM-Scl antibodies associated with
an overlap syndrome), whereas AFA and anti-RNAP are
seen with dcSSc. Anti-Th/To, anti-RNAP and AFA are
associated with a less favorable prognosis with a higher
frequency of organ involvement, contrary to what is seen
in those with anti-PM-Scl antibodies.
Anti-Ku antibodies might have a role in identifying CTD
patients with overlap syndrome involving features of sclero-
derma in the absence of other autoantibodies such as anti-
PM-Scl or anti-U1-RNP antibodies. Anti-Ro antibodies are
identified in the sera of SSc patients with Sjögren syn-
drome. Anti-Sm antibodies are rarely seen in patients with
SSc unless there are features of SLE overlap. When
present, they predict a poor prognosis with frequent renal
involvement. Anti-U1-RNP antibodies are usually seen in
association with CTD overlaps, specifically with Raynaud’s
phenomenon, joint involvement, myositis, lcSSc, and a
more favorable outcome. Although not seen in association
with thrombosis in patients with SSc, inconsistent findings
of associations with myocardial ischemia and pulmonary
hypertension indicate a need for further study before any
clear place of aPL determinations in patients with SSc can
be recommended. Similarly, the clinical relevance of more
newly recognized autoantibody systems in patients with
SSc, particularly ANCA, anti-endothelial cell antibodies and
anti-fibrillin-1, needs more study.
Much like the SSc, these disease-associated autoantibod-
ies differ in their frequencies, associated clinical manifes-
tations, pathophysiology, and ethnic and genetic
associations. When used correctly they can be a clinically
relevant and useful tool in patient management.
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